Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study

2018 ◽  
Vol 66 (3) ◽  
pp. 1193-1211 ◽  
Author(s):  
Tenielle Porter ◽  
Samantha C. Burnham ◽  
Lidija Milicic ◽  
Greg Savage ◽  
Paul Maruff ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Longitudinal Study ◽  
Cognitive Decline ◽  
Disease Risk ◽  
Polygenic Risk Score ◽  
Preclinical Alzheimer’S Disease ◽  
Prospective Longitudinal Study ◽  
Polygenic Risk ◽  
Prospective Longitudinal

Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study

Neurology ◽  
1996 ◽  
Vol 46 (3) ◽  
pp. 661-665 ◽  
Author(s):  
M. C. Tierney ◽  
J. P. Szalai ◽  
W. G. Snow ◽  
R. H. Fisher ◽  
A. Nores ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Longitudinal Study ◽  
Prospective Longitudinal Study ◽  
Prospective Longitudinal

Cognitive predictors of incident Alzheimer's disease: A prospective longitudinal study.

1997 ◽  
Vol 11 (3) ◽  
pp. 413-420 ◽  
Author(s):  
Brent J. Small ◽  
Agneta Herlitz ◽  
Laura Fratiglioni ◽  
Ove Almkvist ◽  
Lars Bäckman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Longitudinal Study ◽  
Prospective Longitudinal Study ◽  
Cognitive Predictors ◽  
Prospective Longitudinal

scholarly journals Impact of hearing loss and vestibular decline on cognition in Alzheimer’s disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECkO)

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e039601
Author(s):  
Joyce Bosmans ◽  
Cathérine Jorissen ◽  
Patrick Cras ◽  
Angelique Van Ombergen ◽  
Sebastiaan Engelborghs ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Hearing Loss ◽  
Longitudinal Study ◽  
Study Protocol ◽  
Cognitive Test ◽  
Secondary Outcome ◽  
Prospective Longitudinal Study ◽  
Prospective Longitudinal ◽  
Mci Due To Ad

IntroductionDementia is a prevalent disease affecting a growing number of the ageing population. Alzheimer’s disease (AD) is the most common cause of dementia. Previous research investigated the link between hearing loss and cognition, and the effect of vestibular dysfunction on cognition. Hearing loss and, to a lesser extent, vestibular decline both result in a decreasing cognitive function. However, their interaction should not be underestimated. The aim of this study is to assess the effect of hearing loss, vestibular decline and their interaction on cognition in people suffering from mild cognitive impairment (MCI) and dementia due to AD (ADD).Methods and analysisWe designed a prospective longitudinal study to assess the effect of hearing loss and vestibular decline on cognition. A total of 100 cognitively impaired elderly (between 55 and 84 years of age), consisting of 60 patients with MCI due to AD and 40 patients with ADD will be included. The control group will consist of individuals with preserved cognition group-matched based on age, hearing level and vestibular function. A comprehensive assessment is performed at baseline, 12-month and 24-month follow-ups. The primary outcome measure is the change in the Repeatable Battery for the Assessment of Neuropsychological Status adjusted for Hearing-impaired individuals total score, a cognitive test battery assessing different cognitive domains. Secondary outcome measures include additional neuropsychological assessments, cortical auditory-evoked potentials, and evaluation of general and disease-specific health-related quality of life. Variables include cognitive, audiological and vestibular evaluation. Variance analyses will assess the effect of hearing loss and vestibular decline on cognition. More precisely, the link between hearing loss and non-spatial cognitive functioning, the effect of vestibular decline on spatial cognition and the impact of both factors on the rate of conversion from MCI due to AD to ADD will be investigated.Ethics and disseminationThe study protocol was approved by the ethical committee of the Antwerp University Hospital on 4 February 2019 with protocol number B300201938949. The findings will be disseminated through peer-reviewed publications and conference presentations.Trial registration numberClinicalTrials.gov Registry (NCT04385225).

scholarly journals P4-496: MYELOID CELL-SPECIFIC ALZHEIMER'S DISEASE POLYGENIC RISK SCORE PREDICTS NEURODEGENERATION AND Aβ-RELATED COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS

2019 ◽  
Vol 15 ◽  
pp. P1503-P1504
Author(s):  
Hyun-Sik Yang ◽  
Tian Ge ◽  
Hilary Finucane ◽  
Philip L. De Jager ◽  
Reisa A. Sperling
Keyword(s):  
Alzheimer’S Disease ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Risk Score ◽  
Myeloid Cell ◽  
Polygenic Risk Score ◽  
Cognitively Normal ◽  
Polygenic Risk

scholarly journals Polygenic risk score for Alzheimer’s disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project

2020 ◽  
Vol 16 (S4) ◽  
Author(s):  
Sven J. van der Lee ◽  
Jarith L. Ebenau ◽  
Iris E. Jansen ◽  
Inge M.W. Verberk ◽  
Philip Scheltens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Risk Score ◽  
Subjective Cognitive Decline ◽  
Polygenic Risk Score ◽  
Polygenic Risk ◽  
Science Project

IC-P-044: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease

2015 ◽  
Vol 11 (7S_Part_1) ◽  
pp. P37-P38
Author(s):  
Stephanie A. Schultz ◽  
Elizabeth A. Boots ◽  
Ryan J. Dougherty ◽  
Burcu F. Darst ◽  
Sherman Yu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Score ◽  
Csf Biomarkers ◽  
Polygenic Risk Score ◽  
Preclinical Alzheimer’S Disease ◽  
Polygenic Risk

scholarly journals Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting

Genes ◽  
2020 ◽  
Vol 11 (5) ◽  
pp. 501
Author(s):  
Jack Euesden ◽  
Sivakumar Gowrisankar ◽  
Angela Xiaoyan Qu ◽  
Pamela St. Jean ◽  
Arlene R. Hughes ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cognitive Decline ◽  
Clinical Utility ◽  
Phase Iii ◽  
Polygenic Risk Score ◽  
Polygenic Risk ◽  
Genome Wide ◽  
A Genome

Introduction: Alzheimer’s disease (AD) is a progressive and irreversible neurological disease. The genetics and molecular mechanisms underpinning differential cognitive decline in AD are not well understood; the genetics of AD risk have been studied far more assiduously. Materials and Methods: Two phase III clinical trials measuring cognitive decline over 48 weeks using Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog, n = 2060) and Clinical Dementia Rating-Sum of Boxes (CDR-SB, n = 1996) were retrospectively genotyped. A Genome-Wide Association Study (GWAS) was performed to identify and replicate genetic variants associated with cognitive decline. The relationship between polygenic risk score (PRS) and cognitive decline was tested to investigate the predictive power of aggregating many variants of individually small effect. Results: No loci met candidate gene or genome-wide significance. PRS explained a very small percentage of variance in rates of cognitive decline (ADAS-cog: 0.54%). Conclusions: These results suggest that incorporating genetic information in the prediction of cognitive decline in AD currently appears to have limited utility in clinical trials, consistent with small effect sizes estimated elsewhere. If AD progression is more heritable soon after disease onset, genetics may have more clinical utility.

Sign in / Sign up

Export Citation Format

Share Document